At 9.6% CAGR, Europe Embolization Devices Market is Projected to be Worth US$ 1,671.99 Million by 2031, Says Business Market Insights

According to Business Market Insights' research, the Europe embolization devices market was valued at US$ 886.97 million in 2024 and is expected to reach US$ 1,671.99 million by 2031, registering a CAGR of 9.6% from 2025 to 2031. Burgeoning demand for minimally invasive techniques and new product developments and marketing approvals innovation are among the critical factors attributed to the Europe embolization devices market expansion.

Embolization is a minimally invasive method used to block blood flow to targeted areas, such as tumors or abnormal blood vessels, by introducing embolic agents via catheters. This method has found wide application in treating AVMs, aneurysms, and certain types of cancer. The preference for such techniques has been on the rise due to their benefits over traditional surgical procedures, including reduced hospital stays, lower complication rates, and faster recovery times.

In uterine fibroid treatment, uterine artery embolization offers an alternative to the conventional treatment approach, such as hysterectomy. A study published in the Journal of Vascular and Interventional Radiology noted that uterine artery embolization had success rates of over 90%, significantly reducing symptoms while preserving the functioning of the uterus, which is particularly appealing among women of reproductive age. Additionally, older individuals often have comorbidities that make them poor candidates for traditional surgical procedures, thus increasing the demand for minimally invasive options. For instance, transarterial chemoembolization (TACE) has become a widely adopted first-line therapy in treating hepatocellular carcinoma (HCC), a common liver cancer in elderly patients. The use of microspheres and drug-eluting beads in TACE helps enhance the HCC treatment. In addition to blocking blood supply, these advanced embolic agents effectively deliver localized chemotherapy to the tumor, improving therapeutic efficacy while reducing systemic side effects. The National Cancer Institute reports that TACE can extend median survival in intermediate-stage HCC patients to 20 months, offering a safer alternative to surgical resection.

Bioresorbable embolic materials have emerged as another development in the embolic devices market; these materials offer temporary occlusion and are gradually absorbed by the body, reducing long-term complications and enabling future treatment options. As healthcare systems worldwide shift toward minimally invasive and cost-effective interventions, patients and clinicians increasingly prioritize treatment options that minimize trauma, recovery time, and complications. Thus, embolization provides a minimally invasive alternative to traditional surgeries, offering targeted treatment, symptom relief, and enhanced quality of life for patients. These benefits are driving the adoption of embolization devices in clinical practice.

On the contrary, complications arising during or after embolization hamper the growth of Europe embolization devices market.

Based on type, the Europe embolization devices market is segmented into embolization coils, plugs, beads, glues, and others. The embolization coils segment held 61.0% share of the Europe embolization devices market in 2024, amassing US$ 540.66 million. It is projected to garner US$ 1,043.27 million by 2031 to expand at 10.0% CAGR during 2025-2031. The embolization coils segment is further sub segmented into central application and peripheral application.

Based on application, the Europe embolization devices market is segmented into neurology, peripheral vascular disease, oncology, urology, and others. The neurology segment held 41.0% share of the Europe embolization devices market in 2024, amassing US$ 363.72 million. It is projected to garner US$ 711.74 million by 2031 to expand at 10.2% CAGR during 2025-2031.

Based on end user, the Europe embolization devices market is segmented into hospitals, ambulatory centers, and others. The hospitals segment held 56.2% share of the Europe embolization devices market in 2024, amassing US$ 498.66 million. It is projected to garner US$ 968.77 million by 2031 to expand at 10.1% CAGR during 2025-2031.

Based on country, the Europe embolization devices market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany held 28.9% share of Europe embolization devices market in 2024, amassing US$ 256.04 million. It is projected to garner US$ 495.50 million by 2031 to expand at 10.0% CAGR during 2025-2031.

Key players operating in the embolization devices market are Medtronic Plc; Cook Medical Holdings LLC; Stryker Corp; Boston Scientific Corp; Terumo Corp; Johnson & Johnson; Abbott Laboratories; NeuroSafe Medical Co. Ltd; Wallaby Medical; Sirtex Medical Ltd; GEM srl; Penumbra Inc.; Balt; Lepu Medical Technology Beijing Co Ltd; INVAMED; Meril Life Sciences Pvt Ltd; Merit Medical Systems Inc; and Lifetech Scientific Corp, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com